NVO : Summary for Novo Nordisk A/S Common Stock - Yahoo Finance

U.S. Markets closed

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
35.25-0.12 (-0.34%)
At close: 4:02PM EST

35.48 0.23 (0.65%)
After hours: 6:39PM EST

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close35.37
Bid0.00 x
Ask0.00 x
Day's Range35.13 - 35.40
52 Week Range30.89 - 57.81
Avg. Volume3,088,422
Market Cap81.7B
PE Ratio (TTM)16.31
Earnings DateN/A
Dividend & Yield1.12 (3.15%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire11 hours ago

    NVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017

    NEW YORK, Feb. 22, 2017 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased ...

  • PR Newswire13 hours ago

    Canadian News Media Challenged to See the Whole Picture When Reporting on Obesity

    MISSISSAUGA, ON, Feb. 22, 2017 /CNW/ - The Canadian Obesity Network, in partnership with Novo Nordisk Canada Inc., is calling on Canadian media to re-examine how people living with obesity are portrayed in news stories and to use non-biased, respectful images. Often, the media use images to accompany news stories that depict people living with obesity from unflattering angles, focusing on the abdomen or lower body with the head cut out of the frame, and frequently consuming unhealthy food or engaged in sedentary activity.1 Widespread use of these stereotypical "fat-shaming" images can promote weight bias and discrimination, a significant cause of distress in people living with obesity. "We want to work with the media to encourage a shift from the use of imagery that depicts people living with obesity in a negative light, to one that looks at the whole picture," said Dr. Arya Sharma, Founder and Scientific Director of the Canadian Obesity Network.

  • Market Realist3 days ago

    Sanofi’s Unique Foothold in Diabetes and Cardiovascular

    Sanofi has reorganized its diabetes and cardiovascular franchise, making it one of the largest revenue contributors to the pharmaceutical business.